Platelet aggregate emboli produced in patients during cardiopulmonary bypass with membrane and bubble oxygenators and blood filters

Microembolism during cardiopulmonary bypass: a comparison of bubble oxygenator with arterial line filter and membrane oxygenator alone

Microemboli can be detected in the cerebral circulation during cardiopulmonary bypass with transcranial Doppler. They are likely to be responsible for the microvascular occlusions that have been seen in the retina and they may contribute to neuropsychological damage that has been demonstrated after cardiac surgery. Twenty patients undergoing routine coronary artery bypass graft surgery were allocated to either a Harvey 1700 bubble oxygenatorwith a Pall 40μ arterial line filter or a Harvey 4000 membrane oxygenator with no arterial line filter. All cases received pulsatile flow perfusion with core cooling to 28°C. A standard surgical technique was used with distal anastomoses performed during cold cardioplegic arrest and proximal anastomoses performed with coronary perfusion during systemic rewarming. Microembolic events were measured by the counting of flow disturbances over the pattern of pulsatile flow as detected by Doppler. Median bypass time was 69 minutes (range 45-95) for the bubbler group and 79 minutes (range 50-115) for the membrane group. The microembolic event count was normalized to the number of events per 15 minute period of bypass. The median number of microembolic events per 15 minute period of bypass was 28 (range 6-54) for the bubble group and 21 (range 10-65) for the membrane group. There were no significant differences between the lengths of bypass between the two groups (Mann-Whitney p = 0.202) or the number of microemboli recorded per 15 minute period of bypass (Mann-Whitney p = 0.224). We conclude that the previously demonstrated excess generation of gaseous microemboli from bubble oxygenators over membrane oxygenators is negated by the use of a 40μ arterial line filter with the bubble oxygenator.

Haemocompatibility of membrane and bubble oxygenators

During clinical hypothermic cardiopulmonary bypass (CPB), the haemocompatibility of six groups of membrane oxygenators (Cobe CML2, Shiley M2000, Maxima, Bard HF4000, Bard HF5000, Capiox E has been studied in 60 patients having open-heart surgery. A standardized anaesthetic and perfusion protocol was used, during which the abilityof the perfusionist to achieve target blood gas values (PaO2 20kPa and PaCO2 5.3kPa: alpha-stat) using inline electrodes was assessed. Haemocompatibility was evaluated by measurement of platelet numbers and function, betathromboglobulin (BTG), plasma haemoglobin, complement (C3a des Arg) and white blood cell (WBC) count pre- and post-CPB. Platelet and WBC numbers were also measured every five minutes throughout CPB.

All oxygenators allowed the perfusionist to control blood gases adequately to prescribed levels. There were only minor differences in the degree and pattern of platelet depletion, reduction in platelet aggregation, elevation of BTG and C3a des Arg observed between oxygenator groups, which did not appear to be influenced by membrane type (flat plate versus hollow fibre). The membrane oxygenator haematological data was amalgamated with that obtained in previous clinical studies using membrane and bubble oxygenators (Cobe CML, Polystan Venotherm, Harvey H 1700, Bentley BIO-10, Bentley 1 0B, Bentley 1 OPlus, Gambro 10 and Shiley S100A HED) in which a similar evaluation protocol was employed.

Comparison of the percentage change in platelet count when the pre- and post-CPB values were compared, demonstrated statistically significantly less platelet depletion (p <0.001 ) in the membrane oxygenator groups (-0.2 ± 8.3%) when compared to the bubble oxygenator groups (-21.7 ± 8.7%). A significantly lower percentage rise in BTG was also observed in the membrane oxygenator group when compared to the bubble oxygenator groups (p <0.001 ). All oxygenator groups showed elevation of both WBC count and plasma haemoglobin with a nonspecific fall in platelet aggregation over the period of bypass but no significant differences could be found between the two types of oxygenator.

Membrane oxygenators, when compared to bubble oxygenators, exhibit lower GME production and improved haemocompatibility and allow superior blood gas control. Membrane oxygenators manifestly must be the oxygenator type of choice for clinical CPB.

Haematological effects of a depth absorption arterial line filter during extracorporeal circulation

An arterial line filter (Swank High Flow 6000) was used during extracorporeal circulation (ECC) in 21 of 45 patients undergoing coronary artery bypass grafting, to study haematological effects. The mean age was 60 (41-69) years. All patients had obstructions of at least three coronary artery branches. Average ECC and aortic crossclamp times, drainage via chest tubes until the first day after surgery, total transfusions of blood products and haemolysis did not differ in the two groups. After 90 minutes of ECC, leukocyte counts were significantly lower in the filter group whereas haematocrit, counts of erythrocytes, lymphocytes and platelets, platelet volume, fibrinogen concentration and fibrinopeptide A were similar. Release of β-thromboglobulin and platelet factor 4 were significantly higher in the filter group. No clinically significant adverse haematological effects were observed with use of the arterial line filter, although there were indications of more pronounced platelet damage in the filter group.

A clinical evaluation of the performance characteristics of one membrane and five bubble oxygenators: haemocompatibility studies

The haemocompatibility of five different bubble oxygenators (Polystan venotherm, Harvey H-1700, Bentley BIO-10, Gambro 10 and Shiley S-100A HED) and one membrane oxygenator (Cobe CML) have been evaluated during standardized clinical perfusion for open-heart surgery in 48 adult patients. Control of arterial PO2 and PCO2 was an important feature of the evaluation protocol. Over the period of cardiopulmonary bypass (CPB) there was a marked difference in the mean percentage reduction in platelet count in the different oxygenator groups. Only 1% reduction in platelet count occurred with the Cobe CML membrane oxygenator group compared with, in the bubble oxygenator groups, 7% for the Gambro 10, 16% for the Harvey H-1700, 19% for the Shiley S-100A HED, 24% for the Bentley BIO-10 and 31% for the Polystan venotherm. The post bypass platelet count was significantly lower than the prebypass value in all oxygenator groups ( p < 0.05) except the Cobe CML and Gambro 10. The two oxygenator groups with the largest percentage reduction in platelet count (Polystan venotherm and Bentley BIO-1 0) demonstrated a significant reduction ( p < 0.05) in platelet aggregation over the period of bypass. Platelet depletion in the Harvey H-1700. Shiley S-100A HED, Bentley BIO-10 and Polystan venotherm oxygenators was associated with a significant fall ( p < 0.05) in mean platelet volume during the first 35 minutes of CPB due to the removal from the circulation of large, young, functionally more active platelets. Erythrocyte damage was minimal in all oxygenator groups and only a minor degree of leucopenia could be demonstrated during the first five minutes of CPB. Cardiotomy suction was not associated with significant changes in platelet numbers or platelet aggregation. When selecting the oxygenator for use in patients undergoing open-heart surgery, gas transfer characteristics and GME production together with the superior preservation of platelet numbers and function in the membrane oxygenator group and variable degree of platelet depletion and reduction in platelet aggregability demonstrated in the five bubble oxygenator groups, must be taken into account.

A double blind clinical trial of Iloprost during cardiopulmonary bypass

Twenty patients undergoing elective coronary surgery were randomized to receive either the prostacyclin analogue Iloprost (Zk 36374) 5 ng/kg/min for 30 minutes before cardiopulmonary bypass (CPB) increasing to 10 ng/kg/min during CPB, or placebo, to investigate any beneficial effect on platelet preservation, or protection of the central nervous system during clinical CPB. Originally 50 patients were to have entered the trial, but unacceptable hypotensive effects occu rred in five patients who received Iloprost, lead i ng to early data analysis. No significant improvement in platelet number, volume or function; bleeding time; arterial line filter δ dry weight; retinal microembolism; or neuropsychological function, attributable to Iloprost, could be identified. The role and optimal dose of Iloprost in clinical CPB remains to be established.

Formal heparin anticoagulation protocol improves safety of charcoal-based liver-assist treatments

Extracorporeal devices have had limited effectiveness in liver failure due to consequences of inadequate anticoagulation. The purpose of this study was to evaluate an anticoagulation protocol developed for Liver Dialysis Unit (LDU) treatments. Twelve patients underwent 19 LDU treatments for acetaminophen overdose (n = 1), subacute liver failure (n = 1), and refractory encephalopathy in cirrhosis (n = 10). The initial 6 patients (group 1) were treated according to the manufacturer's recommendations. The subsequent 6 patients (group 2) were treated using a formal heparin anticoagulation protocol that included 2000 units in prime solution and 30 units/kg induction, activated clotting time (ACT) measurements, and heparin administered by dose-response curve to maintain 300-second ACT. Protamine reversal was used. Treatments were well tolerated and equally effective in both groups. Adequate (ACT > or = 250 seconds) and therapeutic (ACT 250-350 seconds) anticoagulation was maintained more consistently in group 2 (90.9% vs 50.0%, p < 0.0001; and 77.4% vs 45.8%, p < 0.001). There was less consumption of fibrinogen (12.1% vs 43.3%, p < 0.005) and platelets (13.8% vs 29.9%, p < 0.05) and a trend for less blood product used (8.3 vs 15.8 units/patient, p = 0.13) and fewer complications (16.7% vs 66.7%, p = 0.15) in group 2. Anticoagulation using ACT monitoring, heparin dose-response curves, and a target ACT of 300 seconds improves the safety of LDU treatments.

Surface modification of a segmented polyetherurethane using a low-powered gas plasma and its influence on the activation of the coagulation system

A medical grade segmented polyetherurethane (PEU) was treated with a low-powered gas plasma using O(2), Ar, N(2) and NH(3) as the treatment gases. Changes in the surface functional group chemistry were studied using X-ray photoelectron spectroscopy. The wettability of the surfaces was examined using dynamic contact angle measurements and the surface morphology was evaluated using atomic force microscopy. The influence of the surface modification to the polyurethane on the blood response to the polyetherurethane was investigated by measuring changes in the activation of the contact phase activation of the intrinsic coagulation cascade. The data demonstrate that the plasma treatment process caused surface modifications to the PEU that in all cases increased the polar nature of the surfaces. O(2) and Ar plasmas resulted in the incorporation of oxygen-containing groups that remained present following storage in an aqueous environment. N(2) and NH(3) plasmas resulted in the incorporation of nitrogen-containing groups but these were replaced with oxygen-containing groups following storage in the aqueous environment. In all plasma treatments there was a lowering of contact phase activation compared to the untreated surface, the N(2) and NH(3) treatments dramatically so.

Activated neutrophils and platelet microaggregates impede blood filterability through microchannels during simulated extracorporeal circulation

BACKGROUND

Neutrophil sequestration and platelet microaggregates in organ capillaries have been implicated in the inflammatory response associated with cardiopulmonary bypass. We examined the filterability of neutrophils and platelet microaggregates through silicon microchannels during simulated extracorporeal circulation. We hypothesize that blood contact with artificial surfaces over time decreases the ability of neutrophils, platelets, and their aggregates to pass through microchannels.

METHODS

Fresh human blood from donors (n = 9) was recirculated for 120 minutes in a simulated extracorporeal circuit. Blood samples were obtained from a donor at 0, 30, 60, and 120 minutes of recirculation. The microchannel transit time and the flow behavior of blood cells were evaluated by a silicon microchannel array flow analyzer. CD11b, L-selectin, and F-actin of neutrophils were measured by flow cytometry. Neutrophil and platelet counts and platelet aggregation to adenosine diphosphate were measured.

RESULTS

The microchannel transit time was prolonged during recirculation, reaching 185.9% +/- 25.6% of baseline at 120 minutes. The video microscope showed that neutrophils and platelet microaggregates plugged the microchannels. CD11b, L-selectin, and F-actin levels changed significantly by 120 minutes. Platelet counts decreased and platelet aggregability was attenuated.

CONCLUSIONS

Simulated extracorporeal circulation caused a progressive loss in the ability of neutrophils, platelets, and their aggregates to pass through the microchannels independent of neutrophil adhesion molecule expression.

The evolution of cardiopulmonary bypass: lessons to be learned

John Gibbon conceived cardiopulmonary bypass (CPB) and performed the first intracardiac repair using extracorporeal perfusion in 1953. This achievement stimulated rapid development of the knowledge base and equipment necessary for accurate diagnoses and successful intracardiac operations. In the early 60s increasing evidence indicated that exposure of blood to nonendothelial cell surfaces produced bleeding and thrombotic complications and a massive inflammatory response. Early efforts to discover a synthetic, nonthrombogenic surface gave way to efforts to control the 'whole-body inflammatory response' by pharmacological means. These efforts are ongoing; progress is slow; and heparin is still required for most applications of extracorporeal perfusion technology. Nevertheless, CPB now enables over one million cardiac surgical operations each year. Future progress and the development of artificial internal organs that process blood depend upon control of the blood-surface interface without anticoagulants.

The use of leucocyte-depleting and conventional arterial line filters in cardiac surgery: a systematic review of clinical studies

Although various forms of arterial line filter have been available for use during cardiopulmonary bypass (CPB) for 30 years, their use is not universal. The aim of this review was to seek evidence of the clinical benefit of using conventional or leucocyte-depleting arterial line filters during bypass. A literature search revealed 28 relevant clinical studies. Despite the wide variety of patient populations, types of filter and outcome measures utilized in studies, a few conclusions are possible. Whereas conventional filtration has the definite effect of reducing neuropsychological deficit post-CPB, the results of studies using the leucocyte-depleting filter are less clear cut. Leucocyte-depleting filters have potential for reducing inflammatory mediated heart and lung injury, however it is recommended that any additional benefit of leucocyte-depleting filters over conventional filters should be further tested by randomized controlled trials of sufficient size.

Platelets and cardiopulmonary bypass

Exposure of blood to an extracorporeal circulation, such as CPB, causes a variety of physiological responses. Haematological derangements are just one of many potential dangers to the patient who undergoes CPB. The paradox of CPB-related problems with the haematological system is that there are some factors tipping the balance towards a bleeding tendency, and others that favour a prothrombotic state. Both of these issues must be dealt with independently to create the safest environment for surgery. It has been demonstrated that platelets play a key role in both haemostatic dysfunction and thrombotic complications of CPB. Much has been achieved, both clinically and in the laboratory, in the understanding of the precise role platelets play in these events, but the exact mechanisms involved have yet to be completely identified. As research progresses, our understanding will increase, but until then clinical practice must be dictated by the current evidence available.

Head and Heart: Neuropsychological Reaction and Arterial Line Filtration during Cardiopulmonary Bypass

As part of a prospective study of neuropsychologic reactions after cardiopulmonary bypass and their relation to arterial line filters, 44 patients who underwent elective cardiac operations were randomized into two groups. Group A had a 40-micron nylon screen filter in the arterial line. No arterial filter was used in group B. Neuropsychological examinations of all patients were conducted before and at a mean of 8 days after the operation on a double blind basis by a single trained psychologist. The tests included the Wechsler Memory Scale, the trail-making test, the Hamilton Anxiety Rating Scale, and the Hamilton Rating Scale for Depression. The 2 groups were otherwise similar with respect to preoperative neurologic and intellectual status, anesthetic methods, duration of operation, operative procedures performed, and the time spent in the intensive care unit. Surprisingly, there was a highly significant improvement in all four test scores after surgery. There were no statistically significant differences in the test scores between the two groups but considerable inter-patient performance variability was noted. The arterial line filter did not appear to have an effect on test scores. Routine use of an arterial filter remains questionable.

Biocompatibility of heparin-coated membrane oxygenator during cardiopulmonary bypass

The biocompatibility of the cardiopulmonary bypass (CPB) circuit, in which an oxygenator is solely heparinized, was assessed by systemic inflammatory reactions as an indicator during CPB. Fourteen patients, 11 males and 3 females, underwent coronary artery bypass surgery and were randomly divided into 2 groups of 7 patients each. For the heparin-coated oxygenator group (Group H), a heparin-coated membrane oxygenator was used in the CPB circuit, and in the control (Group C) an uncoated membrane oxygenator was employed. Systemic inflammatory reactions, such as platelet activation, prostaglandin production, complement activation, and activated granulocyte released substance, were measured prior to, during, and 6 h after CPB. The number of platelets decreased after protamine administration in both groups (14.5 +/- 4.7 x 10(4)/microliters in Group H and 13.8 +/- 8.7 x 10(4)/microliters in Group C) and returned to baseline levels in Group H while it remained decreased in Group C at 6 h after CPB. The platelet factor 4 level was significantly lower in Group H (181 +/- 40 ng/ml) than in Group C (297 +/- 131 ng/ml) after protamine administration. Thromboxane-B2 (TXB2) rose during CPB in both groups; however, there were significantly different levels of TXB2 between the 2 groups at 60 min after CPB (293 +/- 258 pg/ml in Group H versus 408 +/- 120 pg/ml in Group C) and after protamine administration (259 +/- 122 pg/ml in Group H versus 709 +/- 418 pg/ml in Group C). Plasma concentrations of granulocyte elastase were significantly lower in Group H at 30, 60 and 90 min, immediately after, and post-CPB than those of Group C.(ABSTRACT TRUNCATED AT 250 WORDS)

The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning

BACKGROUND AND PURPOSE

Microemboli have been implicated in the etiology of neuropsychological deficits after cardiopulmonary bypass. This study examined the incidence of high-intensity transcranial signals (microemboli) and their relation to changes in neuropsychological performance after surgery.

METHODS

Transcranial Doppler ultrasonography was used to measure middle cerebral artery blood flow velocity and detect microemboli. The number of high-intensity transcranial signals was determined and related to a neurological examination and absolute changes in neuropsychological performance as well as the number of patients considered to exhibit a neuropsychological deficit. Data were available on 100 consenting patients undergoing routine cardiopulmonary bypass. Fifty of the patients were randomly assigned to a procedure that included a 40-microns arterial line filter, and 50 had the procedure without any arterial line filter.

RESULTS

Significantly more patients were found to have neuropsychological deficits in the group without the arterial line filter at both 8 days (P < .05) and 8 weeks (P < .03) after surgery. In addition, more "soft" neurological signs were found in the nonfiltered group 24 hours after surgery (P < .05). More high-intensity transcranial signals were found in the nonfiltered group, and the number of high-intensity transcranial signals was found to be related to the likelihood of a patient having a neuropsychological deficit at 8 weeks.

CONCLUSIONS

These data suggest that neuropsychological deficits after routine cardiopulmonary bypass are related to the number of microemboli delivered during surgery. Furthermore, the numbers of microemboli may be reduced by including a 40-microns filter on the arterial line.

Biomaterials in cardiopulmonary bypass

The improved utilization of biomaterials in cardiopulmonary bypass is dependent on polymer science and technology, procedures for blood compatibility assessment, optimization of biomaterial/antithrombotic agent combinations and the interpretation of clinical data.

Effect of prostacyclin PGI2 on cardiopulmonary bypass-induced lung injury

Lung injury produced by cardiopulmonary bypass (CPB) is clinically characterized as postperfusion pulmonary dysfunction syndrome. The roles of humoral factors, altered perfusion modes and the occurrence of diffuse microembolism have been subjects of a number of studies. This paper presents the effectiveness of a platelet inhibiting drug, PGI2 in preventing occlusive microaggregates in the pulmonary circulation. In a series of experimental dog studies using a PGI2 dosage protocol of 10 ng/kg/minute for 30 minutes prior to the onset of CPB followed by 20 mg/kg/minute during CPB, the following effects have been observed: 1) Preservation of platelet numbers during CPB (p < 0.01 versus controls; n = 16). 2) Significant reduction in platelet aggregation during CPB (p < 0.01; n = 16). 3) Insignificant hypotensive effect at normal levels of peripheral vascular resistance (n = 16). 4) Occlusive fibrin, leucocytes and small platelet-based microaggregates obstructing pulmonary arterioles in six of the seven control dogs but in none of the dogs receiving PGI2 infusion. 5) No evidence of perivascular or intra-alveolar oedema, interstitial inflammatory cell infiltrates or haemorrhage was seen in either group of dogs. The controversy existing in relation to the possible therapeutic role of PGI2 and, in particular, its ability to prevent occlusive microaggregates in the arterioles and capillaries of vital organs should encourage further clinical studies of PGI2 and its derivatives during cardiac surgery.

Aprotinin in perspective

Aprotinin is a nonspecific serine protease inhibitor extracted from bovine lung. It was first used during cardiopulmonary bypass to inhibit plasmin-induced complement activation. By chance significant reductions of blood loss and blood requirements were noted in treated patients. Subsequent investigation showed improved hemostasis to result from protection of platelet adhesive receptors (Gp Ib) at the onset of cardiopulmonary bypass. Without aprotinin the contact system of plasma is massively activated on first passage through the cardiopulmonary bypass circuit. Activation of the intrinsic coagulation pathway causes thrombin formation, which impairs platelet adhesive function. Aprotinin blocks contact activation of the kallikrein system during cardiopulmonary bypass and in synergy with heparin prevents thrombin formation through inhibition of the intrinsic clotting cascade. It is likely that neither thrombin nor platelets become involved in the blood-foreign surface contact activation process in aprotinin-treated patients. The fact that the hemostatic process is affected from the very beginning of cardiopulmonary bypass is substantiated by the fact that low-dose aprotinin therapy (2 x 10(6) KIU aprotinin added to the pump prime) leads to the same preservative effect on Gp Ib receptors and blood loss as continuous high-dose infusion (6 x 10(6) KIU) throughout the whole surgical procedure. In the presence of heparin aprotinin prolongs the activated clotting time and the in vitro activated partial thromboplastin time. This has important implications for heparin dosage. An inhibitory effect on the endothelial cell anticoagulant function may also have consequences during hypothermic low flow and circulatory arrest states.(ABSTRACT TRUNCATED AT 250 WORDS)

Perioperative stroke. Part II: Cardiac surgery and cardiogenic embolic stroke

The major mechanism of stroke in cardiac surgery is embolization. The risk is higher in intracardiac than in extracardiac surgery. The incidence of stoke associated with CABG is about 5%. The cerebral protective properties of isoflurane and thiopentone, acid-base management, and monitoring of cerebral perfusion during cardiopulmonary bypass are discussed. Prophylactic carotid endarterectomy for patients with asymptomatic carotid disease before cardiac surgery is not necessary. Symptomatic carotid disease increases the risk of stroke, and the management of patients who have both symptomatic coronary and carotid artery diseases is discussed. Cardiogenic embolism is probably responsible for many perioperative strokes. Patients with atrial fibrillation, valvular disease, and prosthetic heart valves are at high risk of cardiogenic embolism. Strokes associated with cardioversion, pacemaker insertion, coronary arteriography and angioplasty are explored.

Demonstration of cerebral microemboli occurring during coronary artery bypass graft surgery using fluorescein angiography

Coronary artery bypass graft surgery is associated with an unacceptably high incidence of neurological and neuropsychological complications (Breur et al., 1981; Smith, 1988). The main cause of cerebral dysfunction following this type of surgery is probably cerebral microembolism (Dutton et al., 1974; Taylor, 1986). The eye is an outgrowth of the brain and therefore is uniquely suitable for the study of cerebral microcirculation. Retinal fluorescein angiography has been employed during this surgical procedure to demonstrate the changes which occur in the cerebral microcirculation during operation.

Dipyridamole for coronary artery bypass surgery

A randomized trial to compare the effects of oral and intravenous dipyridamole was conducted in 58 patients undergoing coronary artery bypass graft (CABG) surgery. Preoperative oral administration of dipyridamole resulted in lower plasma drug concentrations in the early postoperative period than perioperative intravenous administration. Postoperative platelet counts were highest in the patients receiving intravenous dipyridamole, intermediate in those receiving oral dipyridamole and lowest in the control group. Postoperative blood loss was significantly reduced with both oral and intravenous dipyridamole. A second randomized trial was conducted in an additional 40 patients undergoing CABG surgery to evaluate the effects of dipyridamole on myocardial platelet and leukocyte deposition and the cardiac release of thromboxane. Twenty patients received intravenous dipyridamole perioperatively. Autologous platelets and leukocytes were labeled with 111In and 99mTc respectively and were infused before release of the crossclamp. Myocardial biopsies were obtained after aortic declamping and indicated that platelets and leukocytes were deposited in the myocardium during reperfusion. Dipyridamole reduced both platelet and leukocyte deposition. Cardiac release of thromboxane B2 occurred in the early postoperative period and was reduced by dipyridamole. In conclusion, dipyridamole preserved platelets and reduced postoperative bleeding and blood product transfusions in patients undergoing CABG surgery. Dipyridamole also reduced cardiac platelet deposition and thromboxane release and may reduce perioperative ischemic injury.

Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery

The effects of infusion of Iloprost (ZK 36374), a prostacyclin analogue, on platelet function, postoperative blood loss and microaggregate deposition on filters and oxygenators were studied in patients undergoing routine coronary operations. In this double-blind randomized study of 50 male patients, 25 received Iloprost and 25 a placebo. Platelet deposition was assessed using Indium-labelled platelets. Comparison of Iloprost and placebo groups showed the mean number of platelets to be significantly higher in the Iloprost group at the end of cardiopulmonary bypass and in early postoperative recovery. Similarly, spontaneous aggregation of platelets was higher in the placebo group. The mean percentages of platelets sequestrated in the extracorporeal circuit were significantly higher in the placebo group. There was no difference in either the amount or pattern of postbypass bleeding between Iloprost and the control patients. Infusion of the tested drug was responsible for significant hypotension, which was correctable with fluid administration alone. Thus, Iloprost diminishes the fall in circulatory platelet count during cardiopulmonary bypass, preserves platelet function, diminishes platelet deposition on filters and oxygenators, but also causes arterial hypotension.

Blood conservation with membrane oxygenators and dipyridamole

Cardiopulmonary bypass induces platelet activation and dysfunction, which result in platelet deposition and depletion. Reduced platelet numbers and abnormal platelet function may contribute to postoperative bleeding. A membrane oxygenator may preserve platelets and reduce bleeding more than a bubble oxygenator, and the antiplatelet agent dipyridamole may protect platelets intraoperatively and reduce bleeding postoperatively. A prospective randomized trial was performed in 44 patients undergoing elective coronary artery bypass grafting to assess the effects of the membrane oxygenator and dipyridamole on platelet counts, platelet activation products, and postoperative bleeding. Patients who were randomized to receive a bubble oxygenator and no dipyridamole had the lowest postoperative platelet counts, the greatest blood loss, and the most blood products transfused. Platelet counts were highest and blood loss was least in patients randomized to receive a membrane oxygenator and dipyridamole (p less than .05). A bubble oxygenator with dipyridamole and a membrane oxygenator without dipyridamole resulted in intermediate postoperative platelet counts and blood loss. Arterial thromboxane B2 and platelet factor 4 concentrations were elevated on cardiopulmonary bypass in all groups. Both the membrane oxygenator and dipyridamole were independently effective (by multivariate analysis) in preserving platelets. Optimal blood conservation was achieved with a membrane oxygenator and dipyridamole.

Dipyridamole reduced myocardial platelet and leukocyte deposition following ischemia and cardioplegia

Urgent coronary revascularization for acute myocardial ischemia results in an increased mortality and morbidity. Deposition of activated platelets and leukocytes into the ischemic myocardium during reperfusion may augment perioperative ischemic injury. Dipyridamole reduces platelet activation and may reduce myocardial deposition and prevent ischemic injury during reperfusion. The effects of dipyridamole on myocardial platelet and leukocyte deposition were evaluated in a canine model of acute regional myocardial ischemia with reperfusion during cardioplegia on cardiopulmonary bypass. Eight dogs underwent left anterior descending (LAD) coronary artery ligation for 45 min followed by cardiopulmonary bypass and release of the ligature during 60 min of cold crystalloid cardioplegic arrest to simulate urgent revascularization. Four dogs were randomized to receive an infusion of dipyridamole perioperatively (50 mg/hr) and 4 dogs served as controls. Autologous platelets were labeled with 111In, leukocytes with 99mTc, and erythrocytes with 51Cr. The labeled cells were infused immediately after cross-clamp release and myocardial biopsies were obtained at 10, 20, 30, and 60 min of reperfusion. Platelets were deposited in the myocardium during reperfusion and four times more platelets were found in the LAD region than the circumflex region. Leukocyte deposition was similar in the LAD and circumflex regions. Dipyridamole reduced both platelet and leukocyte deposition and the reduction was greater in the LAD than in the circumflex region. Myocardial platelet and leukocyte deposition was found after regional ischemia, cardioplegia, and cardiopulmonary bypass. Dipyridamole reduced myocardial platelet and leukocyte deposition and may reduce perioperative ischemic injury.

A Comparison of Defective Platelet Count and Aggregation between the Valve Replacement and Cyanotic Congenital Heart Cases during Cardiopulmonary Bypass

Platelet count and ADP-induced platelet aggregation were studied in 10 single valve replacement (VR) patients and 10 cyanotic congenital heart disease (CCHD) patients undergoing cardiopulmonary bypass (CPB). The mean platelet count dropped to 78% in VR group and 73% in CCHD group at 30 minutes CPB as compared with the prebypass levels (being corrected for haemodilution). The mean prebypass platelet aggregation value was 65·5% ± 7·5% (Mean ± SEM) in VR group and 56·5% ± 5·2% in CCHD group; the values dropped to 54·2% ± 4·5% and 28·2% ± 4·8% respectively in VR and CCHD groups ( P < 0·01) at 30 minutes CPB. Both groups had a slight further drop at the end of the CPB, but only CCHD group had a further drop in platelet aggregation function after protamine administration. Mean plasma haemoglobin was much higher in the CCHD group than that in VR group at the termination of the bypass ( P < 0·05). Increased blood transfusion volumes were needed and greater blood losses noticed in the CCHD group. A significant negative correlation ( r = 0·5044. P < 0·05) was found between platelet function measured at the termination of CPB and postoperative bleeding. Cardiopulmonary bypass in patients with CCHD appears to be associated with greater platelet dysfunction and this results in more serious haemostatic defects after CPB. It is necessary to have further studies of the defective haemorrhagic status in these patients. More advanced perfusion techniques should be applied to preserve platelets during cardiopulmonary bypass.

Retinal microembolism during cardiopulmonary bypass demonstrated by fluorescein angiography

Fluorescein angiography was used to study retinal microvascular perfusion in 20 patients undergoing coronary artery surgery. Colour retinal photographs and fluorescein angiograms were obtained preoperatively and at 5-14 days postoperatively. In 10 patients retinal fluorescein angiograms were also obtained intraoperatively during cardiopulmonary bypass, and all were found to have retinal microvascular occlusions after 40-160 min of extracorporeal circulation. 3 patients had in addition focal leakage of fluorescein, and 6 had foci of abnormal drainage of dye. These changes are consistent with retinal microembolism, and appeared to have resolved by the time of the postoperative study. No new pathological features appeared in the retina after surgery. Intraoperative fluorescein angiography of the retina may prove valuable for investigation of cerebrovascular microembolism in the territory of the internal carotid artery during cardiopulmonary bypass in man.

Cerebral blood flow during cardiopulmonary bypass in man: effect of arterial filtration

Cerebral blood flow was recorded in 39 patients undergoing cardiac surgery by intraarterial injection of xenon 133. There were three subgroups of patients: 10 patients had a 20 micron arterial filter (Johnson) and 11 a 40 micron filter (Pall), and 18 had no arterial filtration. All patients had a 40 micron (Pall) filter in the coronary suction line. Significant changes in cerebral blood flow occurred during extracorporeal circulation (p less than 0.0001). For all patients cerebral blood flow increased from a resting prebypass level of 30 to 46 and 57 ml/100 g a minute during initial and stable hypothermic extracorporeal circulation respectively. Both measurements were obtained at 26 degrees C and the recordings were made on average 12 and 55 minutes after the extracorporeal circulation was started. During rewarming cerebral blood flow increased to 64, 53, 41, and 36 ml/g a minute at 31 degrees, 33 degrees, 35 degrees, and 37 degrees C respectively, and when measured four and 16 minutes on average after bypass it was 44 and 41 ml/100 g a minute. This general brain hyperperfusion was noticed in all patients with a high enough mean blood pressure to produce hyperaemia. Interposing 20 and 40 micron arterial filters reduced cerebral blood flow but did not prevent this hyperaemia. The cerebral autoregulation, which maintains a constant cerebral blood flow within wide limits of perfusion pressures, was not affected by arterial filtration. The lower limit of blood pressure at which a further reduction in blood pressure was followed by a reduction in cerebral blood flow was around 60 mm Hg in all three groups.

Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study

In a double-blind, placebo-controlled trial of 40 patients requiring aortocoronary vene transplant surgery, prostacyclin (PGI2) was infused in a dose of 8 ng/kg/min throughout cardiopulmonary bypass. When compared with the placebo-group, the patients treated with PGI2 were found to have significantly higher platelet counts 60(2) and 90 minutes after onset of extra-corporeal circulation (EC). Although this platelet preservation by PGI2 was accompanied by less degranulation of alpha-granula, total antithrombin III (AT III) as well as active AT III and factor Xa inhibitory activity did show comparable results in both treatment groups. In the early phase of EC coagulation factors (fibrinogen, prothrombin and factor VII) exhibited a trend in favour of higher plasma levels in the PGI2-treated group. The same results were found for plasminogen. F VIII-related antigen and complement factors (C3, C4, C3 activator) did not show any difference between the two treatment groups. Bleeding times, blood loss and renal function also did not exhibit any significant differences between the two groups of patients. Except for one control (60 minutes after onset of EC) hemodynamic parameters were not significantly different between the two patient groups. Whether the trend in favour of a lower mortality in PGI2-treated patients can be confirmed, will be up to further studies with greater numbers of patients.